These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 31527456)

  • 1. Frequent
    Hanna RM; Khalid M; El-Nour LA; Selamet U
    Antibiotics (Basel); 2019 Sep; 8(3):. PubMed ID: 31527456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral administration of ruxolitinib in psoriasis vulgaris: A case report of plaque psoriasis accompanied by myelofibrosis secondary to polisitemia vera successfully treated with oral ruxolitinib.
    Çetinarslan T; Aydoğdu İ; Ermertcan AT
    J Dermatol; 2024 Oct; ():. PubMed ID: 39428662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera.
    Wei JJ; Kallenbach LR; Kreider M; Leung TH; Rosenbach M
    JAAD Case Rep; 2019 Apr; 5(4):360-361. PubMed ID: 31008168
    [No Abstract]   [Full Text] [Related]  

  • 4. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
    Cinats A; Heck E; Robertson L
    Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib.
    March-Rodriguez Á; Bellosillo B; Álvarez-Larrán A; Besses C; Pujol RM; Toll A
    Ann Dermatol; 2019 Apr; 31(2):204-208. PubMed ID: 33911570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib.
    Prakash K; Richman D
    BMC Infect Dis; 2019 Mar; 19(1):287. PubMed ID: 30917797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway.
    Delen E; Doğanlar O
    J Korean Neurosurg Soc; 2020 Jul; 63(4):444-454. PubMed ID: 32492985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus kinase inhibitors: jackpot or potluck?
    Pavithran K; Pande SB
    Oncol Rev; 2012 Mar; 6(1):e13. PubMed ID: 25992203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib.
    Abidi MZ; Haque J; Varma P; Olteanu H; Guru Murthy GS; Dhakal B; Hari P
    Case Rep Hematol; 2016; 2016():2389038. PubMed ID: 27843657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.
    Mesa RA; Scherber RM; Geyer HL
    Leuk Lymphoma; 2015 Jul; 56(7):1989-99. PubMed ID: 25644746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus kinase JAK1 maintains the ovarian reserve of primordial follicles in the mouse ovary.
    Sutherland JM; Frost ER; Ford EA; Peters AE; Reed NL; Seldon AN; Mihalas BP; Russel DL; Dunning KR; McLaughlin EA
    Mol Hum Reprod; 2018 Nov; 24(11):533-542. PubMed ID: 30247637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis.
    Hirano A; Yamasaki M; Saito N; Iwato K; Daido W; Funaishi K; Ishiyama S; Deguchi N; Taniwaki M; Ohashi N
    Respir Med Case Rep; 2017; 22():87-90. PubMed ID: 28721333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib: a targeted treatment option for patients with polycythemia vera.
    Vaddi K; Verstovsek S; Kiladjian JJ
    Blood Lymphat Cancer; 2016; 6():7-19. PubMed ID: 31360077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Miliary TB and COVID-19 Coinfection in a Patient With a History of Post-polycythemia Vera Myelofibrosis Treated With Ruxolitinib: A Case Report.
    Loutsou M; Georgakopoulou VE; Roussakis N; Chadia K; Steiropoulos P
    Cureus; 2024 Jul; 16(7):e63791. PubMed ID: 39100065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.
    Manduzio P
    Ther Clin Risk Manag; 2017; 13():169-177. PubMed ID: 28243106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK-inhibitors in dermatology: current evidence and future applications.
    Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
    J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unexpected Neurological Symptoms of Ruxolitinib: A Case Report.
    Furia F; Canevini MP; Federici AB; Carraro MC
    J Hematol; 2020 Dec; 9(4):137-139. PubMed ID: 33224394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Ruxolitinib for the Simultaneous Treatment of Severe Refractory Ulcerative Colitis and Polycythemia Vera.
    Swei EC; Fox CM; Bowles DW; Rizeq MN; Onyiah JC
    ACG Case Rep J; 2022 Jan; 9(1):e00741. PubMed ID: 35018293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.